A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia (ALLR17)

For: acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma

A Reduced Intensity Conditioning Regimen with CD3-Depleted Hematopietic Stem Cells to Improve Survival for Patients with Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation

For: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Hodgkin lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS)

Reduced duration Stanford V Chemotherapy with low-dost tailored-field radiation therapy for favorable risk pediatric Hodgkin lymphoma

For: Hodgkin lymphoma

HLA - Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less than 2 Years of Age with Hematologic Malignancies

For: Leukemias (high risk hematologic malignancies)

Phase II Study Incorporating Pegylated Interferon In The Treatment For Children With High-Risk Melanoma

For: Melanoma

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies

For: Refractory or relapsed leukemia (AML, T-ALL, CML, JMML), T-cell lymphoma, and myelodysplastic syndrome

A Phase I Trial of the Combination of Oxaliplatin and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas

For: Recurrent or refractory solid tumors or lymphomas

A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and Irinotecan (CamptosarTM) Given Orally in Children with Refractory Solid Tumors (AstraZeneca Protocol IRUSIRES0181)

For: Refractory solid tumors including glioblastoma, rhabdomyosarcoma, neuroblastoma, and osteosarcoma

A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies

For: Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia

Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects

For: Ewing sarcoma; rhabdomyosarcoma; primitive neuroectodermal tumors (PNET) of the musculoskeletal system; soft tissue sarcomas; other bone sarcomas; chordoma

Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children with Diffuse Intrinsic Pontine Glioma

For: Diffuse intrinsic pontine glioma

A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) during and after Radiotherapy in the Treatment of Patients with Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma

For: Intracranial high-grade glioma and unfavorable low-grade glioma

Risk-Adapted Therapy for Children Less Than 3 Years of Age with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma

For: Embryonal brain tumors, choroid plexus carcinoma or ependymoma

A Phase III Randomized Clinical Trial to Compare Standard Therapy with Alternative Therapy for the Prevention of Secondary Stroke and the Management of Iron Overload in Pediatric Subjects with Sickle Cell Anemia and Previous Stroke

For: Sickle cell anemia

The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1 Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen

For: Infectious Disease

A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (Bay 43-9006, NSC#724772, IND#69896) in Children with Refractory Solid Tumors or Refractory Leukemias (ADVL0413)

For: All Leukemias, Solid Tumors

Killer Immunoglobulin-Like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study (AAML05P1)

For: Refractory and relapsed acute myelogenous leukemia (AML)

Perinatal Neuroblastoma: Expectant Observation - A Children's Oncology Group Pilot Study

For: Neuroblastoma

A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants

For: HIV (Human Immunodeficiency Virus) infection in pregnant women

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults with HIV Infection Being Treated with Antiretroviral Therapy Containing Tenofovir Compared to Those Being Treated with Antiretroviral Therapy Not Containing Tenofovir

For: Human Immunodeficiency Virus (HIV)

A Phase I/II Dose Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias

For: Refractory or relapsed acute leukemia

Phase III Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma (ACNS0232)

For: Germinoma

A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors (AGCT0132)

For: Germ cell tumor

A Randomized Phase II Study of Bortezomib (PS-341), Velcade, IND 58443, NSC 681239) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients with Relapsed/Refractory Hodgkin Disease

For: Hodgkin lymphoma

Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

For: Neuroblastoma

A Study to Determine the Activity of SCH 717454 in Subjects with Osteosarcoma or Ewing’s Sarcoma that has Relapsed after Standard Systemic Therapy (SCH Protocol: PO4720) (US IND BB-100343)

For: Solid tumors, osteosarcoma, Ewing sarcoma

A Phase I Clinical Trial of AZD2171 In Children With Recurrent or Progressive Central Nervous Systems (CNS) Tumors

For: Recurrent or Progressive Central Nervous System (CNS) Tumors

Phase I and Pharmacokinetic Study of Enzastaurin (LV317615) in Children and Adolescents with Refractory Primary CNS Tumors

For: Brain tumors

A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449

For: Brain tumors

Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy

For: Adrenocortical tumors

Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

For: Wilms Tumor

Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide with or without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

For: Rhabdomyosarcoma (embryonal/botryoid/spindle cell subtypes)

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)

For: Rhabdomyosarcoma